This trial is active, not recruiting.

Conditions drug effect disorder, platelet procoagulant activity deficiency
Sponsor Beijing Anzhen Hospital
Start date May 2014
End date December 2015
Trial size 74 participants
Trial identifier NCT02198053, azliquan


Different antiplatelet drugs played various role in coronary artery disease. The mechanisms were unclear. Platelet reactivation maybe was one of major causes. Compared with clopidogrel, Ticagrelor is more powerful antiplatelet drug. However, because of increased bleeding and dyspnea risk, both loading double dose and following second dose time had potential risk and inconvenient in routine clinical work, especially in elective PCI of comparable stable patients in Chinese. The benefit and risk should be balanced in such patients. The investigators supposed loading single dose and followed by second routine time dose was superior to clopidogrel and safer than ticagrelor previously prescribed.

United States No locations recruiting
Other countries No locations recruiting

Study Design

Observational model case control
Time perspective prospective
Ticagrelor with a loading dose of 180mg followed by 90 mg twice per day
Ticagrelor with a dose of 90mg followed by 90 mg twice per day .

Primary Outcomes

Platelet reactivity
time frame: 1 year

Eligibility Criteria

Male or female participants of any age.

Inclusion Criteria: coronary artery disease, percutaneous coronary intervention Exclusion Criteria: high risk bleeding patient, allergic to the drugs

Additional Information

Official title Effect of 180 mgTicagrelor Compared With 90 mg Ticagrelor on Platelet Reactivity in Patients Undergoing Elective PCI.
Description All admission patients were divided into two groups, the first group were prescribed loading dose (180 mg) ticagrelor, the second group were prescribed with 90 mg ticagrelor. We measured both platelet activity and platelet reactivity using the LTA at baseline, pre-operation and post-operation. All bleeding or dyspnea events were recorded in hospital period. Primary endpoints: platelet activity, platelet reactivity using the LTA and safety events were recorded in hospital period.
Trial information was received from ClinicalTrials.gov and was last updated in July 2015.
Information provided to ClinicalTrials.gov by Beijing Anzhen Hospital.